- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT01172899
Bariatric Surgery in Children. (BASIC)
The BASIC Trial. Morbid Obesity in Children and Adolescents: a Prospective Randomised Trial of Conservative Treatment Versus Surgery
Rationale:
In the Western world overweight and obesity is an increasing problem both in adults and in children. In youth, it is associated with early death and a number of co-morbidities including metabolic and endocrine changes, increased inflammatory status, cardiovascular abnormalities, nonalcoholic fatty liver disease, and impaired quality of life.
The standard treatment for morbid obesity in children is by combined life style interventions. However, the medium and long term effects of dietetic interventions, behaviour therapy and medication is relatively poor. In adults bariatric surgery shows good results with up to 30% weight reduction in 3 years. The preliminary results in youth are similar, but surgery in this age group is relatively uncommon. In the Netherlands surgery in this age group is only allowed in clinical trials, until the benefits and risks have been established. (National Health Authorities)
Objective:
To determine if surgery gives a superior weight and body mass index (BMI) reduction than combined life style interventions in adolescents with morbid obesity and to assess its effect on obesity associated co-morbidity.
Study design:
Prospective randomised interventional study.
Study population:
Morbidly obese children, aged 14 - 16 years, with sex and age adjusted BMI >40 kg/m2 or >35 kg/m2 with co-morbidity.
Intervention:
Bariatric surgery by laparoscopic adjustable gastric band (LAGB) or combined life style interventions
Main study parameters/endpoints:
Primary endpoints: weight loss, loss of excess weight, loss of excess BMI. Secondary endpoints: Body composition, pubertal development, metabolic and endocrine changes, inflammatory status, cardiovascular abnormalities, non-alcoholic steatohepatitis, brain development, quality of life, and behaviour changes. The potential complications of surgery are monitored.
Обзор исследования
Статус
Условия
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Limburg
-
Maastricht, Limburg, Нидерланды, 6202ZA
- Maastricht University Medical Center
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Aged 14 to 16
Age and sex adjusted BMI >40 kg/m2 or >35 kg/m2 with associated co-morbidity.
* Associated co-morbidity includes: glucose intolerance, type 2 diabetes, hypertension, pseudotumor cerebri, acanthosis nigricans, obstructive sleep apnoea syndrome, depression, arthropathies, non-alcoholic steatohepatitis and dyslipidemia.
- > 1 year multidisciplinary organized weight reducing attempts with less than 5% weight loss
- Demonstrate decisional capacity
Exclusion Criteria:
- Psychologically not suitable
- Pre-menarche or bone age <15 years in boys
- Obesity associated to other disorders such as hypothyroidism
- Syndromal disorders such as Prader-Willi syndrome
- Severe cardiorespiratory impairment (ASA class 3 or higher)
- Insufficiently fluid in the Dutch language
- Unwillingness to adhere to follow-up programmes
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Одинокий
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Активный компаратор: Контрольная группа
|
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
|
Экспериментальный: Laparoscopic adjustable gastric band
|
Laparoscopic gastric band placement.
Combined lifestyle interventions will continue after surgery.
Control group will receive standard therapy consisting of combined lifestyle interventions.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Weight
Временное ограничение: 6 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
6 months
|
|
Weight
Временное ограничение: 12 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
12 months
|
|
Weight
Временное ограничение: 24 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
24 months
|
|
Weight
Временное ограничение: 36 months
|
Weight loss, excess weight loss and loss of excess BMI.
|
36 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Body composition
Временное ограничение: 12 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
12 months
|
|
Pubertal development
Временное ограничение: 6 months
|
Follow-up of hormonal status and Tanner stages.
|
6 months
|
|
Metabolic and endocrine changes
Временное ограничение: 6 months
|
6 months
|
|
|
Inflammatory status
Временное ограничение: 6 months
|
Measurement of serum inflammatory markers.
|
6 months
|
|
Cardiovascular abnormalities
Временное ограничение: 6 months
|
6 months
|
|
|
Non-alcoholic fatty liver disease
Временное ограничение: 6 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
6 months
|
|
Quality of life changes
Временное ограничение: 6 months
|
6 months
|
|
|
Behaviour changes
Временное ограничение: 6 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
6 months
|
|
Operative complications
Временное ограничение: up to 36 months
|
Early and late complications are being monitored
|
up to 36 months
|
|
Effects on sleep architecture
Временное ограничение: 6 months
|
6 months
|
|
|
Brain development
Временное ограничение: 6 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
6 months
|
|
Body composition
Временное ограничение: 24 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
24 months
|
|
Body composition
Временное ограничение: 36 months
|
Next to anthropometric measurements, bone mineral content, bone density, lean bodymass and fat percentage will be assessed.
|
36 months
|
|
Pubertal development
Временное ограничение: 12 months
|
Follow-up of hormonal status and Tanner stages.
|
12 months
|
|
Pubertal development
Временное ограничение: 24 months
|
Follow-up of hormonal status and Tanner stages.
|
24 months
|
|
Pubertal development
Временное ограничение: 36 months
|
Follow-up of hormonal status and Tanner stages.
|
36 months
|
|
Metabolic and endocrine changes
Временное ограничение: 12 months
|
12 months
|
|
|
Metabolic and endocrine changes
Временное ограничение: 24 months
|
24 months
|
|
|
Metabolic and endocrine changes
Временное ограничение: 36 months
|
36 months
|
|
|
Inflammatory status
Временное ограничение: 12 months
|
Measurement of serum inflammatory markers.
|
12 months
|
|
Inflammatory status
Временное ограничение: 24 months
|
Measurement of serum inflammatory markers.
|
24 months
|
|
Inflammatory status
Временное ограничение: 36 months
|
Measurement of serum inflammatory markers.
|
36 months
|
|
Cardiovascular abnormalities
Временное ограничение: 12 months
|
12 months
|
|
|
Cardiovascular abnormalities
Временное ограничение: 24 months
|
24 months
|
|
|
Cardiovascular abnormalities
Временное ограничение: 36 months
|
36 months
|
|
|
Non-alcoholic fatty liver disease
Временное ограничение: 12 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
12 months
|
|
Non-alcoholic fatty liver disease
Временное ограничение: 24 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
24 months
|
|
Non-alcoholic fatty liver disease
Временное ограничение: 36 months
|
Next to an ultrasound of the liver, serum levels of ALT, AST, ALP and GGT are measured.
CCL-2 is used as a surrogate marker to assess liver disease.
|
36 months
|
|
Quality of life changes
Временное ограничение: 12 months
|
12 months
|
|
|
Quality of life changes
Временное ограничение: 24 months
|
24 months
|
|
|
Quality of life changes
Временное ограничение: 36 months
|
36 months
|
|
|
Effects on sleep architecture
Временное ограничение: 12 months
|
12 months
|
|
|
Effects on sleep architecture
Временное ограничение: 24 months
|
24 months
|
|
|
Effects on sleep architecture
Временное ограничение: 36 months
|
36 months
|
|
|
Behaviour changes
Временное ограничение: 12 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
12 months
|
|
Behaviour changes
Временное ограничение: 24 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
24 months
|
|
Behaviour changes
Временное ограничение: 36 months
|
Measuring impulsivity and positive reward dominance with a computer task.
|
36 months
|
|
Brain development
Временное ограничение: 12 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
12 months
|
|
Brain development
Временное ограничение: 24 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
24 months
|
|
Brain development
Временное ограничение: 36 months
|
If extra sponsorship can be gained, we will use fMRI and MEG in a subgroup to measure blood oxygen level-dependent (BOLD) brain response to food stimuli.
|
36 months
|
|
Physical activity
Временное ограничение: 6 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
6 months
|
|
Physical activity
Временное ограничение: 12 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
12 months
|
|
Physical activity
Временное ограничение: 24
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
24
|
|
Physical activity
Временное ограничение: 36 months
|
Assessment of physical activity using a questionnaire and an accelerometer.
|
36 months
|
|
Behavior towards food
Временное ограничение: 6 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
6 months
|
|
Behavior towards food
Временное ограничение: 12 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
12 months
|
|
Behavior towards food
Временное ограничение: 24 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
24 months
|
|
Behavior towards food
Временное ограничение: 36 months
|
Behavior towards food is assessed by questionnaires and a computerized model for wanting and liking of food.
|
36 months
|
Соавторы и исследователи
Следователи
- Главный следователь: LWE van Heurn, Professor, Maastricht University Medical Center
- Главный следователь: Yvonne Roebroek, PhD Student, Maastricht University Medical Center
- Главный следователь: Givan F Paulus, PhD Student, Spaarne Gasthuis, Haarlem
Публикации и полезные ссылки
Полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Ожидаемый)
Завершение исследования (Ожидаемый)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- NL26279.068.09
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .